相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Determination of fitness and therapeutic options in older patients with acute myeloid leukemia
Jorge E. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Which novel agents will have a clinically meaningful impact in AML at diagnosis?
Alexander E. Perl
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2021)
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
Mikkael A. Sekeres et al.
BLOOD ADVANCES (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience
Lucia Gozzo et al.
FRONTIERS IN PHARMACOLOGY (2020)
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
Naseema Gangat et al.
BLOOD CANCER JOURNAL (2020)
Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia
Felicetto Ferrara et al.
CANCERS (2019)
Recent drug approvals for acute myeloid leukemia
Catherine Lai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
Keith W. Pratz et al.
BLOOD (2019)
How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
Brian A. Jonas et al.
LEUKEMIA (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Matthew S. Davids et al.
CLINICAL CANCER RESEARCH (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety Profile of Venetoclax Monotherapy in Patients with Chronic Lymphocytic Leukemia
John F. Seymour et al.
BLOOD (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
The Temporary Recommendations for Use: A dual-purpose regulatory framework for off-label drug use in France
Albane Degrassat-Theas et al.
HEALTH POLICY (2015)
Adverse drug reactions and off-label and unlicensed medicines in children: a prospective cohort study of unplanned admissions to a paediatric hospital
Jennifer R. Bellis et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: Its correlation with FLT3
S. V. Mehta et al.
NEOPLASMA (2013)
Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells
Twee Tsao et al.
ANNALS OF HEMATOLOGY (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
Gunnar Juliusson et al.
BLOOD (2009)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva et al.
CANCER CELL (2006)
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML)
G Del Poeta et al.
BLOOD (2003)
分享论文
